The CJC-1295 + Ipamorelin stack is one of the most frequently referenced growth hormone secretagogue (GHS) combinations in current peptide research, and interest has only accelerated through 2026 as laboratories continue exploring GH axis physiology, somatotroph signaling, and downstream IGF-1 dynamics.
Here is the mechanism behind why these two compounds are studied together, and what the research shows about the combination versus either compound alone.
Two Pathways, One Goal: Pulsatile GH Release
The combination works because CJC-1295 and Ipamorelin act on two distinct, complementary receptor systems:
- CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH). It binds the GHRH receptor on pituitary somatotrophs, stimulating the synthesis and pulsatile release of growth hormone in a pattern that mimics natural physiological secretion.
- Ipamorelin is a selective ghrelin receptor (GHSR-1a) mimetic. It triggers GH release through a separate pathway, with high selectivity that avoids significantly elevating cortisol or prolactin — a key reason it’s favored over older ghrelin mimetics like GHRP-6.
Because the two pathways are independent, using them together produces a synergistic rather than additive effect on GH pulse amplitude. In preclinical models, the combination produces GH pulse amplitudes averaging 3 to 5 times baseline, compared to roughly 1.5 to 2 times baseline with either compound used alone.
CJC-1295 With DAC vs. Without DAC
A critical distinction in CJC-1295 research is the presence or absence of the Drug Affinity Complex (DAC) modification:
- CJC-1295 with DAC covalently binds to albumin in circulation, extending its half-life to approximately 8 days. This produces sustained, elevated baseline GH and IGF-1 levels rather than discrete pulses — useful for research into chronic GH axis activation.
- CJC-1295 without DAC (sometimes labeled Mod GRF 1-29) has a much shorter half-life (around 30 minutes), producing a GH pulse that more closely resembles natural physiological secretion timing. This variant is generally preferred in combination protocols with Ipamorelin specifically because it preserves the pulsatile pattern rather than flattening it into a sustained plateau.
Most current research combining CJC-1295 with Ipamorelin uses the no-DAC variant for this reason, though both are active areas of investigation depending on the research question (acute pulse dynamics vs. chronic axis activation).
What Researchers Are Studying
Current research interest in this stack spans several domains:
- Body composition: Sustained GH/IGF-1 elevation is studied for effects on lean mass and adipose tissue, relevant to broader metabolic research including the muscle-preservation questions raised by GLP-1 therapy (see our 2026 GLP-1 muscle loss update).
- Sleep architecture: GH release is naturally tied to slow-wave sleep, and Ipamorelin/CJC research often tracks sleep quality markers as a secondary endpoint.
- Pituitary and somatotroph biology: The combination is a useful tool for studying GHRH and ghrelin receptor crosstalk in isolation from other confounding GH secretagogues.
- Safety profile research: Because Ipamorelin is highly selective for GHSR-1a, studies continue to evaluate whether the combination avoids the cortisol/prolactin elevation seen with less selective ghrelin mimetics like GHRP-6 or Hexarelin.
Why This Pairing Specifically
Researchers gravitate toward this particular combination because it isolates two non-overlapping mechanisms cleanly — GHRH receptor agonism and selective ghrelin receptor agonism — without the off-target cortisol/prolactin activity that complicates interpretation when older, less selective secretagogues are used. This makes it a relatively clean model system for studying synergistic GH pulse dynamics.
Ipamorelin is available now through FenaLife Labs for laboratory and preclinical research.
All compounds referenced are for laboratory and preclinical research purposes only. Not approved for human use. Nothing in this article constitutes medical advice.
🔬 Research Compounds Referenced: Ipamorelin 10mg